Neoadjuvant radiotherapy with or without PD-1 inhibitor (Camrelizumab) for resectable hepatocelluar carcinoma with portal vein tumor thrombus: a randomized multicenter controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034582

Enrollment

Unknown

Registered

2020-07-10

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heopatocellular carcinoma

Interventions

experimental group:PD-1 combined with NeoRT

control group:NeoRT

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients consent to join this trial and sign the Informed Consent Form; 2. Male or female aged between 18-75 years; 3. Clinically or pathologically confirmed hepatocellular carcinoma; 4. Resectable lesion with type II/III portal vein tumor thrombus; 5. Liver function: Child-pugh A; 6. ECOG score:0-1; 7. Anticipated survival >= 12 weeks; 8. Without severe systemic disease.

Exclusion criteria

Exclusion criteria: 1. A history of other malignancy; 2. Underwent other invasive treatments.

Design outcomes

Primary

Measure	Time frame
Disease Free Survival;	—

Secondary

Measure	Time frame
Overall survival;Objective response rate of Neoadjuvant treatment;	—

Countries

China

Contacts

Public ContactShuqun Cheng

Eastern Hepatobiliary Surgery Hospital

chengshuqun@aliyun.com+86 021-81875251

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026